Oncology

New Data Reported for Trastuzumab Biosimilars CT-P6 and HLX02 at ESMO 2019

October 1st 2019

By Kelly Davio

Biosimilar trastuzumab is becoming a feature of the biosimilar landscape in both Europe and the United States, with 5 agents (Herzuma, Kanjinti, Ontuzant, Ogivri, and Trazimera) approved in both territories and with additional biosimilars in the drugmakers’ pipelines. During the European Society for Medical Oncology (ESMO) Congress 2019, held in Barcelona, Spain from September 27 to October 1, researchers reported new data from phase 3 studies of 2 such biosimilar products.

ESMO 2019 Features Data on Biosimilar Pegfilgrastim and Filgrastim

September 30th 2019

By Kelly Davio

During the European Society for Medical Oncology (ESMO) Congress 2019, researchers provided a detailed look at a 3-treatment, 6-sequence crossover study for a pegfilgrastim biosimilar, and a separate team presented on the use of biosimilar filgrastim in patients who are being given chemotherapy regimens that involve a rest period of up to 14 days.

Pfizer Confirms It Plans to Launch Bevacizumab Biosimilar on December 31

September 30th 2019

By Kelly Davio

In an email to The Center for Biosimilars®, a Pfizer representative said that, after having agreed to the terms of a settlement with Genentech and Roche that provides the biosimilar developer with global licenses for its product, Pfizer plans to launch its biosimilar bevacizumab, Zirabev, in the US market on December 31, 2019.

"Not So Different": OneOncology Gives a Closer Look at Its Biosimilar Adoption

September 29th 2019

This week on the podcast, we’re speaking with Jeffrey Patton, MD, chief executive officer of Tennessee Oncology, a partner practice of OneOncology, and the president of physician services for OneOncology. Patton shares with us the rationale for the adoption of biosimilars, how patients are responding, and lessons learned.

During ESMO 2019, Researchers Report That Biosimilar SB8 is Equivalent to Avastin in Best ORR

September 28th 2019

By Kelly Davio

During this week’s European Society for Medical Oncology (ESMO) Congress 2019, held September 27 to October 1 in Barcelona, Spain, a research team presented findings from a phase 3 trial of Samsung Bioepis' SB8, a proposed bevacizumab biosimilar referencing Avastin.

In Updated Phase 3 Results, Innovent's Bevacizumab Biosimilar Shows Similarity to Avastin

September 23rd 2019

By Kelly Davio

During last week’s 22nd Annual Meeting of the Chinese Society of Clinical Oncology, held from September 18-22 in Xiamen, China, drug maker Innovent Biologics presented updated results for its proposed bevacizumab biosimilar, IBI305, in an oral session.

Fixed-Dose, Subcutaneous Pertuzumab and Trastuzumab Combination Meets Primary End Point in Phase 3 Study

September 19th 2019

By The Center for Biosimilars Staff

By providing time-saving options for treatment, Roche may be able to secure market share for its innovator biologics if savings in terms of chair time for patients are able to offset the eventual price discounts made available by biosimilar developers for their products.

A Decade of Biosimilar Filgrastim Experience Highlights the Scientific Basis for Extrapolation, Study Says

September 17th 2019

By Kelly Davio

Sandoz’s biosimilar filgrastim was first approved in Europe in 2009 under the name Zarzio (later, the same drug was approved as Zarxio in the United States). Since that time, the number of biosimilars approved for use in the oncology field has grown substantially, and a recent review says that the past decade of experience with biosimilar filgrastim underscores the strong scientific basis for the extrapolation of indications for biosimilars.

Giving Specialty Drugs Outside Hospital Settings Could Save $4 Billion Annually, Report Says

September 9th 2019

By Allison Inserro

A new report released Monday by UnitedHealth Group finds that administering specialty drugs—which are typically injected or infused—in homes or in independent physician offices instead of hospitals could save as much as $4 billion each year.

Howard Burris, MD, FACP, FASCO: Adoption of Anticancer Biosimilars

September 6th 2019

Howard Burris, MD, FACP, FASCO, president of clinical operations and chief medical officer of Sarah Cannon Research Institute, discusses the adoption of oncology biosimilars.